Monica Saenz Castillo, PA
Medical · Raymondville, TXNPI 1619990967
Payments from drug & device makers
Across 135 payments — averaging $15.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$548
- Amgen$360
- Bayer$303
- Novo Nordisk$203
- Abbott$98
- Sanofi-aventis U.S. LLC$74
- plus $526 from 14 others
What the payments were for
- Food & beverage$2,112100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 40 | $548 |
| Amgen | 27 | $360 |
| Bayer | 16 | $303 |
| Novo Nordisk | 12 | $203 |
| Abbott | 4 | $98 |
| Sanofi-aventis U.S. LLC | 5 | $74 |
| Exact Sciences | 4 | $73 |
| AstraZeneca | 4 | $53 |
| Lundbeck LLC | 3 | $47 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $43 |
| Phadia US Inc. | 2 | $41 |
| Amarin Pharma, Inc. | 2 | $37 |
| Astellas Pharma US Inc | 2 | $36 |
| ANI Pharmaceuticals, Inc. | 2 | $35 |
| Johnson & Johnson | 2 | $34 |
| Boehringer Ingelheim | 2 | $33 |
| Sumitomo Pharma America, Inc. | 2 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $29 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$125
How this compares
$2,112 in reported general payments places this provider in the 65th percentile of 1,490 medical providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 153 | $180,020 |
| MounjaroTirzepatide | 151 | $179,478 |
| JardianceEmpagliflozin | 93 | $84,602 |
| RybelsusSemaglutide | 42 | $48,774 |
| FarxigaDapagliflozin Propanediol | 48 | $34,636 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $18,206 |
| Xigduo XrDapaglifloz Propaned/Metformin | 15 | $15,889 |
| EliquisApixaban | 20 | $14,344 |
| LinzessLinaclotide | 23 | $14,310 |
| KerendiaFinerenone | 12 | $12,821 |
| MyrbetriqMirabegron | 23 | $12,086 |
| Tresiba Flextouch U-100Insulin Degludec | 18 | $11,838 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 20 | $11,224 |
| Atorvastatin Calcium | 223 | $1,988 |
| Rosuvastatin Calcium | 165 | $1,605 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $203 | $228,793195 claims |
| Lilly USA, LLCMounjaro | $548 | $179,478151 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $33 | $95,826113 claims |
| AstraZenecaFarxiga | $53 | $34,63648 claims |
| PfizerEliquis | $14 | $14,34420 claims |
| BayerKerendia | $303 | $12,82112 claims |
| Astellas Pharma US IncMyrbetriq | $36 | $12,08623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,490 medical providers in Texas.
Other medical in Raymondville
- Jose de la CerdaSan Antonio$1.1M
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
- Kimberly PoarchDallas$166K
- Erin DuhaimeDallas$150K
- Courtney AldridgeSan Antonio$129K
- Shakira CabreraSan Antonio$116K
- Danny DeckardDallas$101K
- Janine ShinnDallas$84K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.